Taizhou Crene Biotechnology Co., Ltd.
                                                                                                           
Verified Supplier
19 Years
Since 2007
Menu
Chemicals Organic Intermediate

FGF FGFR VEGFR Inhibitors LY2874455 Cas 1254473-64-7

Price Negotiable
Price: Negotiable
MOQ: Negotiable
Delivery Time: Negotiable
Product Description

FGF FGFR VEGFR Inhibitors LY2874455 Cas 1254473-64-7

 

+ AII PRODUCTS

- Prostaglandins - Custom Synthesis - PARP Inhibitors - PI3K Inhibitors - FAK Inhibitors - AKT Inhibitors - C-Kit Inhibitors - VEGFR Inhibitors - c-Met Inhibitors - CDK Inhibitors - CYP17 Inhibitors - DNA/RNA Inhibitors - mTOR Inhibitors - SRC Inhibitors - Others

Product

Size

Price

Stock

Quantity

Get Quotation Now Add to Cart Bulk Inquiry

 

AddThis Sharing Buttons

Share to FacebookFacebookShare to TwitterTwitterShare to PrintPrintShare to EmailEmailShare to PinterestPinterestShare to GmailGmailShare to LinkedInLinkedInShare to Email AppEmail AppShare to TumblrTumblrShare to MoreAddThis

Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.

 

Chemical Information

Product name:LY2874455

Purity:98% min

CAS NO:1254473-64-7

Solubility:DMSO50 mg/mL (112.53 mM)

Molecular Formula:C21H19Cl2N5O2

Package:Package according to customer requirements.

Molecular Weight:444.314

Storage:Store at -20℃

 

Quality control

Remarks

LY2874455 is a novel and potent FGF/FGFR Inhibitor. It exhibits a potent activity against FGF/FGFR-mediated signaling in several cancer cell lines and shows an excellent broad spectrum of antitumor activity in several tumor xenograft models representing the major FGF/FGFR relevant tumor histologies including lung, gastric, and bladder cancers and multiple myeloma, and with a well-defined pharmacokinetic/pharmacodynamic relationship.

 

Related Prodcuts:

ZM-306416; ZM323881; Tyrphostin A9; Orantinib; Brivanib; Foretinib; SU5402; Semaxanib; SAR131675; Lucitanib; Apatinib; SKLB610; Altiratinib; SGI-7079; AZD2932

 

References

[1] Zhao G, et al. Mol Cancer Ther. 2011, 10(11), 2200-2210.

Get in Touch

Have questions about our products or want to discuss a custom order? Our team is ready to help you.

Company Taizhou Crene Biotechnology Co., Ltd.
Location Add: Economic Developed Zone of Taizhou Zhejiang China.

Request A Quote

Please check your email address.
Your message must be at least 20 characters.